The Diagnostic Imaging MRI modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of MRI across the healthcare continuum, including breast, neurological, cardiovascular, prostate imaging, and more.
April 24th 2025
New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?
View More
Lung Cancer Tumor Board®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
2025 International Symposium of Gastrointestinal Oncology (ISGIO)
September 12-13, 2025
Register Now!
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
43rd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 12-14, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
43rd Annual Miami Breast Cancer Conference®
March 5-8, 2026
Register Now!
19th Annual New York GU Cancers Congress™
March 13-14, 2026
Register Now!
Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies
View More
(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice
View More
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
Can AI Automate BPE Assessment of Dense Breasts on MRI?
April 3rd 2024An MRI-based machine learning model demonstrated a comparable background parenchymal enhancement (BPE) hazard ratio to that of manual BPE assessment for breast cancer, according to a study of over 4,500 women with dense breasts.
Are Prostate Biopsies Necessary in Patients with Negative or Equivocal MRIs and Low PSA Density?
April 2nd 2024Up to 48 percent of unnecessary prostate biopsies could be eliminated by limiting biopsy to patients with PI-RADS 4 and higher MRI assessments and a prostate-specific antigen density level below 0.15 ng/mL2, according to a new meta-analysis.
FDA Clears Remote Scanning Support Platform for MRI, CT and PET/CT
March 25th 2024The multimodality system nCommand Lite reportedly facilitates real-time remote imaging guidance on scanning parameters and procedure assessments to licensed technologists for a variety of imaging modalities including CT and MRI.
Emerging Insights on MRI-Guided Transurethral Ultrasound Ablation for Prostate Cancer
March 21st 2024For men with prostate cancer, the use of MRI-guided transurethral ultrasound ablation (TULSA) led to a 92 percent decrease in median prostate volume at one year, according to new research recently presented at Society of Interventional Radiology (SIR) conference.
Study: PET/MRI May Prevent Up to 83 Percent of Unnecessary Biopsies in Men with PI-RADS 3 Lesions
March 15th 2024For men with PI-RADS 3 lesions, PRIMARY scores of 4-5 with PET/MRI had a sensitivity rate of 87.5 percent for clinically significant prostate cancer, according to newly published research.
Study Says Low-Field MRI Offers Sufficient Diagnostic Quality for Detecting Spinal Pathology
March 11th 2024In a study of patients who had lumbar spine MRI exams at 0.55T, 1.5T and 3T, researchers found that 0.55T MRI provided acceptable diagnostic quality across all sequences for varying pathologies including degenerative joint disease, compression fractures and osseous metastatic disease.
Can Autonomous AI Help Reduce Prostate MRI Workloads Without Affecting Quality?
March 1st 2024Based on findings from a multicenter study of over 1,600 patients, researchers at the European Congress of Radiology suggest the inclusion of autonomous artificial intelligence (AI) triage could facilitate up to a 75 percent reduction in prostate MRI reading workload.
ECR Study Examines Key Predictive Factors for Metastasis in Patients with High-Risk Prostate Cancer
February 28th 2024Sixty-five percent of patients with newly diagnosed high-risk prostate cancer may have extraprostatic extension on MRI, and PSMA PET/CT findings suggest those with Gleason scores of eight or higher have more than double the risk of metastasis, according to a new study presented at the European Congress of Radiology (ECR).
Can Non-Contrast Abbreviated MRI be a Viable Alternative for HCC Surveillance?
February 27th 2024A new meta-analysis noted pooled sensitivity and specificity rates of 83 percent and 91 percent, respectively, for the use of non-contrast abbreviated MRI in surveillance of hepatocellular carcinoma (HCC).